MARATTO

article · BioMedInformatics

Toward Clinically Dependable AI for Brain Tumors: A Unified Diagnostic–Prognostic Framework and Triadic Evaluation Model

2026Open accessSuez University

Abstract

Artificial intelligence (AI) has shown promising performance in brain tumor diagnosis and prognosis; however, most reported advances remain difficult to translate into clinical practice due to limited interpretability, inconsistent evaluation protocols, and weak generalization across datasets and institutions. In this work, we present a critical synthesis of recent brain tumor AI studies (2020–2025) guided by two novel conceptual tools: a unified diagnostic-prognostic framework and a triadic evaluation model emphasizing interpretability, computational efficiency, and generalizability as core dimensions of clinical readiness. Following PRISMA 2020 guidelines, we screened and analyzed over 100 peer-reviewed studies. A structured analysis of reported metrics reveals systematic trends and trade-offs—for instance, between model accuracy and inference latency—rather than providing a direct performance benchmark. This synthesis exposes critical gaps in current evaluation practices, particularly the under-reporting of interpretability validation, deployment-level efficiency, and external generalization. By integrating conceptual structuring with evidence-driven analysis, this work provides a framework for more clinically grounded development and evaluation of AI systems in neuro-oncology.

Research topics

  • Explainable Artificial Intelligence (XAI)
  • Radiomics and Machine Learning in Medical Imaging
  • Artificial Intelligence in Healthcare and Education

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.3390/biomedinformatics6010007

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.